CoChat

Advances in Ophthalmic Optogenetics: Approaches and Applications

Open access

The DOI matches its Crossref record; 96 of the 99 references it cites were found in a registry or an index.

Abstract

Recent advances in optogenetics hold promise for vision restoration in degenerative eye diseases. Optogenetics refers to techniques that use light to control the cellular activity of targeted cells. Although optogenetics is a relatively new technology, multiple therapeutic options are already being explored in pre-clinical and phase I/II clinical trials with the aim of developing novel, safe, and effective treatments for major blinding eye diseases, such as glaucoma and retinitis pigmentosa. Optogenetic approaches to visual restoration are primarily aimed at replacing lost or dysfunctional photoreceptors by inserting light-sensitive proteins into downstream retinal neurons that have no intrinsic light sensitivity. Such approaches are attractive because they are agnostic to the genetic causes of retinal degeneration, which raises hopes that all forms of retinal dystrophic and degenerative diseases could become treatable. Optogenetic strategies can also have a far-reaching impact on translational research by serving as important tools to study the pathogenesis of retinal degeneration and to identify clinically relevant therapeutic targets. For example, the CRY-CIBN optogenetic system has been recently applied to animal models of glaucoma, suggesting a potential role of OCRL in the regulation of intraocular pressure in trabecular meshwork. As optogenetic strategies are being intensely investigated, it appears crucial to consider the opportunities and challenges such therapies may offer. Here, we review the more recent promising optogenetic molecules, vectors, and applications of optogenetics for the treatment of retinal degeneration and glaucoma. We also summarize the preliminary results of ongoing clinical trials for visual restoration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom12020269

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Optogenetic approaches: The favorite models for optogenetic therapy include mouse models, which can be adapted to study and treat different eye-related conditions using various optogenetic techniques.
Figure 1 Optogenetic approaches: The favorite models for optogenetic therapy include mouse models, which can be adapted to study and treat different eye-related conditions using various optogenetic techniques.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Research works printed but not linked: 1

  1. Martel, 2021, Optogenetic GS030 Therapy in Subjects with Retinitis Pigmentosa: Safety and Tolerability Up to Two Years After Treatment Administration in the Phase 1/2a PIONEER Study, Investigative Ophthalmology & Visual Science, 62, 3236

Cited by

See all 41

Metadata

Authors
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y.
Affiliations
  • Stanford Medicine (US)
  • University of Nevada, Reno (US)
Corresponding author
Sun, Yang
Venue
Biomolecules
Publisher
MDPI AG
Published
2022-02-08
Volume
12
Issue
2
Pages
269
ISSN
2218-273X (ISSN-L)
OpenAlex
W4211263455
Cited by
41
References
99
Citations by year
2026: 8 · 2025: 10 · 2024: 7 · 2023: 12 · 2022: 4
FWCI
1.18
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (NIH) / National Eye Institute (NEI) (K08-EY022058; R01-EY025295; F32-EY032775-01; T32-EY027816)
  • U.S. Department of Veterans Affairs (CX001298)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Photoreceptor and optogenetics research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
Keywords
optogenetics, vision restoration, retinal degeneration, glaucoma, retinitis pigmentosa, photoreceptor replacement, light-sensitive proteins, OCRL, intraocular pressure, trabecular meshwork, retinal dystrophy, gene therapy vectors, clinical trials
MeSH terms
Animals, Retina, Retinal Degeneration, Retinitis Pigmentosa, Vision, Ocular, Optogenetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in Ophthalmic Optogenetics: Approaches and Applications. https://app.cochat.ai/papers/10.3390/biom12020269
The paper
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022). Advances in Ophthalmic Optogenetics: Approaches and Applications. Biomolecules. https://doi.org/10.3390/biom12020269

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.